Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) were up 5.1% during mid-day trading on Tuesday . The company traded as high as $2.10 and last traded at $2.05. Approximately 1,378,237 shares were traded during mid-day trading, an increase of 178% from the average daily volume of 495,193 shares. The stock had previously closed at $1.95.
A number of analysts have recently issued reports on BDSI shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $5.00 price objective on shares of BioDelivery Sciences International in a research report on Thursday, March 15th. Seaport Global Securities started coverage on BioDelivery Sciences International in a research report on Friday, January 26th. They issued a “buy” rating and a $5.00 price objective for the company. HC Wainwright set a $5.00 price objective on BioDelivery Sciences International and gave the company a “buy” rating in a research report on Monday, November 27th. ValuEngine cut BioDelivery Sciences International from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Finally, Zacks Investment Research raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Wednesday, February 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $4.25.
The company has a quick ratio of 1.29, a current ratio of 1.52 and a debt-to-equity ratio of 5.37.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Thursday, March 15th. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.05). The firm had revenue of $12.51 million for the quarter, compared to the consensus estimate of $9.83 million. BioDelivery Sciences International had a return on equity of 22.93% and a net margin of 8.52%. analysts predict that BioDelivery Sciences International, Inc. will post -0.72 EPS for the current fiscal year.
In other news, Director Francis E. Odonnell, Jr. sold 113,876 shares of the stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $2.14, for a total transaction of $243,694.64. Following the transaction, the director now owns 319,717 shares in the company, valued at $684,194.38. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mark A. Sirgo sold 709,502 shares of the stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $2.73, for a total value of $1,936,940.46. Following the transaction, the director now owns 1,759,262 shares in the company, valued at approximately $4,802,785.26. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,093,887 shares of company stock worth $2,909,970. 7.73% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN increased its stake in BioDelivery Sciences International by 138.2% during the 3rd quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock worth $105,000 after acquiring an additional 20,599 shares during the period. JPMorgan Chase & Co. bought a new position in BioDelivery Sciences International during the 3rd quarter worth $116,000. Two Sigma Investments LP bought a new position in BioDelivery Sciences International during the 4th quarter worth $166,000. BlueCrest Capital Management Ltd bought a new position in BioDelivery Sciences International during the 4th quarter worth $201,000. Finally, Goldman Sachs Group Inc. bought a new position in BioDelivery Sciences International during the 4th quarter worth $223,000. Institutional investors own 47.93% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “BioDelivery Sciences International (BDSI) Trading Up 5.1%” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://ledgergazette.com/2018/03/22/biodelivery-sciences-international-bdsi-trading-up-5-1.html.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.